The re-import of antisera and other blood fractions to France is projected to decline steadily from $382.26 thousand in 2024 to $219.68 thousand by 2028. This represents a compound annual growth rate (CAGR) of -13.2% over five years. The year-on-year variation indicates a continual decrease in value each year, reflecting a shrinking demand or potential shifts in sourcing strategies in France. The value in 2023 stood significantly higher than the forecasts for 2024 and beyond, indicating a downtrend.
Future trends to watch include advancements in biotechnology that could affect the need for imports, regulatory changes impacting trade, and potential economic factors influencing procurement strategies. Monitoring these elements will provide insights into market behavior and potential stabilization or changes in the demand for these products.
